RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY.

about

RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY.

Item

http://www.wikidata.org/entity/Q48060784

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@en

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@nl

type

Item

label

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@en

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@nl

prefLabel

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@en

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@nl

P1476

RISK OF NEW ONSET TYPE II DM I ...... NT: A NATIONWIDE COHORT STUDY.

@en

P2093

Chun-Yuan Lin

http://www.w3.org/2001/XMLSchema#string

Hong-Song Wang

http://www.w3.org/2001/XMLSchema#string

I-Chia Chien

http://www.w3.org/2001/XMLSchema#string

Ping-Kun Chen

http://www.w3.org/2001/XMLSchema#string

Yu-Hsin Wu

http://www.w3.org/2001/XMLSchema#string

Yuan-Fu Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence.

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials.

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.

Observational studies: cohort and case-control studies.

Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.

Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.

P304

435-443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DA.22489

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26990119

http://www.w3.org/2001/XMLSchema#string